Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application ...

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for ...

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | ...

Regeneron (REGN) announces FDA review of sBLA for Eylea HD to treat macular edema and expand dosing. Read more here.

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial. Novartis ...

Scientists discovered two genes involved in hyperemesis gravidarum, a condition that can cause extreme nausea and vomiting ...

BofA lowered the firm’s price target on Regeneron (REGN) to $547 from $575 and keeps an Underperform rating on the shares based on a lower ...